Investment Thesis
Aptevo Therapeutics is in severe financial distress with collapsing revenue (-74.7% YoY), massive operating losses (-$20.3M on only $3.1M revenue), and negative free cash flow of -$20.4M. Despite adequate liquidity, the company is burning cash at an unsustainable rate with no clear path to profitability, characteristic of a pre-revenue or failed-asset biotech with fundamental business viability concerns.
Strengths
- Strong current ratio of 4.03x provides near-term liquidity runway
- Zero long-term debt eliminates bankruptcy risk from leverage
- Maintains $21.1M cash balance for operational continuity in short-term
Risks
- Revenue collapse of 74.7% YoY indicates loss of commercial traction or product failure
- Operating burn rate of $20.3M annually with only $3.1M revenue is unsustainable
- Negative free cash flow of -$20.4M will deplete $21.1M cash within ~12 months at current burn rate
- Severely negative margins (operating -652%, net -647%) indicate no viable business model
- Pharmaceutical sector with failed commercial execution faces high risk of total equity loss
Key Metrics to Watch
- Quarterly revenue trend - any stabilization or further deterioration
- Cash burn rate and runway months - critical given current trajectory
- Operating expense reduction initiatives - cost control measures
- Quarterly operating cash flow - whether negative trends persist
- Any new partnership, licensing, or asset sale announcements
Financial Metrics
Revenue
3.1M
Net Income
-20.2M
EPS (Diluted)
$-11.42
Free Cash Flow
-20.4M
Total Assets
27.0M
Cash
21.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-652.4%
Net Margin
-647.4%
ROE
-115.9%
ROA
-74.7%
FCF Margin
-654.6%
Balance Sheet & Liquidity
Current Ratio
4.03x
Quick Ratio
2.94x
Debt/Equity
0.00x
Debt/Assets
35.6%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T01:50:11.938013 |
Data as of: 2025-09-30 |
Powered by Claude AI